Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
124.98
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 11th, 5:54 AM EDT
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.
Via Stocktwits · July 10, 2025
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.
Via Benzinga · July 10, 2025
Via Benzinga · July 9, 2025

Via Benzinga · December 11, 2024

Via Benzinga · November 8, 2024
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Via Stocktwits · April 17, 2025
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.
Via Benzinga · April 17, 2025
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.
Via Benzinga · April 10, 2025

Via Benzinga · October 21, 2024

Via Benzinga · August 16, 2024

Via Benzinga · July 30, 2024
Via Benzinga · April 10, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via Investor's Business Daily · January 9, 2025

The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via Investor's Business Daily · December 9, 2024

Via Benzinga · October 21, 2024

Via Benzinga · June 28, 2024

After Monday's panicked global sell-off, markets have calmed down.
Via Investor's Business Daily · August 9, 2024

LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via Investor's Business Daily · August 6, 2024

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
Via The Motley Fool · May 22, 2024